B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in B-cell NHL therapeutics.

Synopsis

There are more than 1.7 million diagnosed prevalent cases of B-cell NHL across 16 pharmaceutical markets.

There are a good number of marketed innovator drugs for the treatment of B-cell NHL, mostly protein/peptide inhibitors and receptor antagonists..
The B-cell NHL pipeline consists of 891 pharmaceutical drugs spanning all stages of development, with more than 6% of molecules in late-stage development.
Commercial sponsors dominate clinical trial development in B-cell NHL, with Italy and the US emerging as the key country for conducting Phase III trials.
During the past 24 months, 28 strategic alliances and 26 merger and acquisitions involving companies developing B-cell NHL assets were successfully completed.
While key players in the marketed drugs space for B-cell NHL are more inclined towards life cycle management, emerging players are focused on launching novel investigational drugs for the treatment.

Scope

GlobalData’s B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the B-cell NHL market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global B-cell NHL market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.